Related Experiment Video
Updated: Mar 9, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Advances in the management of renal cell carcinoma]
Joanna Matuszkiewicz-Rowińska1, Małgorzata Kościelska2
1Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych WUM, Warszawa, Polska, jrowinska@gmail.com.
Abstract:
Renal cell carcinoma accounts for about 3-4% of all malignancies and its incidence is steadily rising. The article presents in short the rationale behind the targeted therapies and provides an update on current therapeutic approaches to metastatic renal cell carcinoma. It also summarizes the most recent developments in the immunotherapy such as immune checkpoint inhibitors, anti-cancer vaccines and chimeric antigen receptors on T cells.
More Related Videos
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Chronic Kidney Disease III: Interprofessional Care
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chronic Kidney Disease IV: Nursing Management
Kidney Transplant III: Nursing Management
Urinary Tract Calculi VI: Surgical Management

